About hepion pharmaceuticals inc - HEPA
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Morristown, NJ.
HEPA At a Glance
Hepion Pharmaceuticals, Inc.
55 Madison Avenue, PMB No. 4362
Morristown, New Jersey 07960
| Phone | 1-732-902-4000 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -13,192,420.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
HEPA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.366 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.41 |
HEPA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
HEPA Liquidity
| Current Ratio | 0.513 |
| Quick Ratio | 0.513 |
| Cash Ratio | 0.129 |
HEPA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -133.455 |
| Return on Equity | -487.033 |
| Return on Total Capital | -1,272.586 |
| Return on Invested Capital | -478.804 |
HEPA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 279.744 |
| Total Debt to Total Assets | 179.707 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |